Matrix Capital Group Inc

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Matrix Capital Group Inc
CRD #33364
SEC #801-61224
CIK #0001906866, 0001410830
AUM
Employees 4 (50% Investors, 50% Brokers)
Fees
Minimum
Phone816-787-0718
Address106 West 32nd Street
New York, NY 10001
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
80064048032016002000200820162025
Fees and Compensation — Form ADV Part 2A (3/30/2016) [Brochure]
ITEM 5 -- FEES AND COMPENSATION
Fees for Investment Advisory Services are based upon a percentage of Assets Under Management
(“AUM”) and generally range from 0.20% to 0.50%, annually. Fees are based on the account’s asset
value as of the last business day of the prior calendar period, depending upon whether fees are paid
monthly or quarterly. Fees are billed monthly or quarterly in arrears as stated in the client’s agreement.
Fees are on a negotiated basis and depend on the degree of complexity associated with the client’s
situation. Fees are provided in a schedule of disclosed fees in each client agreement.

Matrix Capital Group, Inc.                                                                  Page 3

Additional Fees and Expenses. Matrix fees are exclusive of any additional charges, commissions or
fees imposed by custodians, brokers, third party investment managers and other third parties such as
investment manager fees, custodial fees, deferred sales charges, wire transfer and electronic fund fees,
and other fees and taxes on brokerage accounts and securities transactions. Mutual Funds and
exchange traded funds also charge internal management fees, which are disclosed in a fund’s
prospectus, all of which are exclusive of and in addition to Matrix Capital Group’s fee.

Fees Offset By Commission and Other Fees. Management personnel and other related persons of
our firm are licensed as registered representatives of Matrix Capital Group, Inc., a broker-dealer (Please
refer to Item 10, “Other Financial Industry Activities and Affiliations,” for a detailed explanation of these
relationships and important conflict of interest disclosures). This presents a potential conflict of
interest, which gives such personnel and other related persons of the firm an incentive to recommend
investment products based on the compensation received, rather than on a client’s needs.

In their separate capacity(ies), these individuals may earn separate and typical compensation, i.e.,
commissions, 12b-1 fees, “trailing fees” (compensation for allocating client assets to hedge funds) or
other sales-related forms of compensation, for transactions in advisory accounts. As a matter of firm
policy, Matrix takes the following steps with regard to any potential investment as to which either
Matrix or its employees may receive compensation in the form of commissions, trailing fees, etc., in
their capacity as licensed representatives of Matrix Capital Group, Inc. (a FINRA broker-dealer):

    1. Matrix discloses the potential for the firm or its employees to earn such additional
       compensation in advance of the investment being made;

    2. If the client then chooses to make the recommended investment, Matrix excludes all such assets
       from the Assets Under Management as to which Advisory Fees may be paid; and,

    3. Matrix continuously highlights the existence of the excluded assets by showing them as non-
       billed assets on each subsequent billing statement.

In addition to these procedures, Clients always have the option to purchase investment products Matrix
recommends through other brokers or agents that are not affiliated with Matrix.

All applicable and potentially applicable conflicts of interest of which Matrix is aware are fully disclosed
to our clients. For detailed information about how Matrix addresses conflicts that arise, including
procedures used for disclosing conflicts to clients, please refer to Item 10, “Other Financial Industry
Activities and Affiliations.”

Fee Billing. The specific manner in which fees are charged by Matrix is established in a client’s
agreement. Client’s may elect to be billed directly for fees or to authorize Matrix to directly debit the
Client’s account for the amount of the total advisory fee and directly remit that management fee to
Matrix in accordance with applicable custody rules.

Prepayment of Fees. Under no circumstances does Matrix require prepayment of fees.

Matrix Capital Group, Inc.                                                                    Page 4
Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2016) [Brochure]
ITEM 7 -- TYPES OF CLIENTS
Our ideal clients include foundations and high net worth families and individuals and other institutional
clients.
Sector Form 13F Holdings Value ($B)
AURA Biosciences Inc 0.0
 
 
 
 
 
 
 
 
 
 
Holdings by Sector ($B)
151296302011201620212027
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 0 0.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 1 30.0
By Discretionary
Discretionary 0 0.0
Non-Discretionary 1 30.0
Total 1 30.0
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 30.0
Total 1 30.0
EDGAR Form CIK 2011 - 2026
13F-HR [0001410830]
3 [0001410830]
4 [0001410830]
SC 13D [0001410830]
SC 13G [0001410830]
13F-HR [0001906866]
Form 13D/13G Filer Form 13D/13G Subject Filed
Matrix Capital Management Company LP Maze Therapeutics Inc [2025-05-14]
Matrix Capital Management Company LP Zentalis Pharmaceuticals Inc [2022-06-03]
Matrix Capital Management Company LP Forgerock Inc [2022-02-14]
Matrix Capital Management Company LP Perimeter Solutions Sa [2022-02-14]
Matrix Capital Management Company LP AURA Biosciences Inc [2021-11-04]
Matrix Capital Management Company LP Bigcommerce Holdings Inc [2021-02-16]
Matrix Capital Management Company LP Zentalis Pharmaceuticals Inc [2021-02-16]
Matrix Capital Management Company LP Altair Engineering Inc [2020-02-14]
Matrix Capital Management Company LP Adaptive Biotechnologies Corp [2020-02-14]
Matrix Capital Management Company LP Cargurus Inc [2019-02-14]
View All
Firm Profile (Form ADV)
ServesInstitutional
Form 3/4/5 Subject 2011 - 2026
Matrix Capital Management Company LP
Aura Biosciences Inc
GOEL David E
Zentalis Pharmaceuticals Inc
Adaptive Biotechnologies Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
2025-12-15 Sell 7,500,000 $1.33 9,975,000
Aura Biosciences Inc AURA
Common Stock, par value $0.00001 per share (Common Stock)
2023-11-09 Buy 1,560,000 $9.00 14,040,000
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
2023-06-20 Buy 4,760,000 $22.66 107,861,600
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
2022-12-05 Buy 1,250,000 $12.00 15,000,000
Aura Biosciences Inc AURA
Common Stock
2021-11-02 Buy 1,785,000 $14.00 24,990,000
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
2021-11-02 Conversion 2,327,870 $0.00
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
2021-11-02 Conversion 2,327,870
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-10 Sell 30,268 $42.38 1,282,758
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-10 Sell 25,732 $41.47 1,067,106
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-09 Sell 34,302 $41.16 1,411,870
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-09 Sell 215,698 $40.42 8,718,513
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 71,194 $41.21 2,933,905
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 234,295 $38.22 8,954,755
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 75,000 $39.22 2,941,500
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 33,600 $39.97 1,342,992
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 85,911 $41.62 3,575,616
Adaptive Biotechnologies Corp ADPT
Common Stock
2020-07-20 Sell 2,000,000 $40.00 80,000,000
Adaptive Biotechnologies Corp ADPT
Common Stock
2020-01-24 Conversion 2,217,101 $26.50 58,753,176
Adaptive Biotechnologies Corp ADPT
Common Stock
2019-07-01 Conversion 84,359
Adaptive Biotechnologies Corp ADPT
Series E-1 Convertible Preferred Stock · derivative
2019-07-01 Conversion 5,893,716 $0.00
showing 20 of 26 most recent transactions
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com